Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray Pharma mottar CRL från amerikanska FDA för Nilopki™
Regulatory Filings Classification · 92% confidence The document is a corporate press release announcing that Xspray Pharma received a Complete Response Letter (CRL) from the FDA. It does not contain financial results, a report, or any of the specific categories such as earnings release, annual report, or M&A. It is a general regulatory announcement about FDA correspondence, fitting the fallback category for miscellaneous regulatory announcements and compliance notices. Therefore, it is classified as Regulatory Filings (RNS).
2026-06-05 Swedish
Xspray Pharma Receives CRL from U.S. FDA for Nilopki™
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing that Xspray Pharma received a Complete Response Letter (CRL) from the U.S. FDA regarding its New Drug Application (NDA). It does not contain financial statements, voting results, or board/management changes, nor is it a specific report like an annual report or earnings release. It constitutes a general regulatory announcement required under market abuse regulations, fitting the fallback category of Regulatory Filings (RNS).
2026-06-05 English
Kommuniké från årsstämma i Xspray Pharma AB (publ) 12 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release summarizing the resolutions and voting outcomes from the Xspray Pharma AB annual general meeting held on 12 May 2026. It lists decisions on approval of accounts, discharge of liability, dividend, board and auditor elections, incentive programs, and share issuance authorizations—all outcomes of shareholder votes. This fits the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-12 Swedish
Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release titled “Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026” summarizing the resolutions passed at the AGM (adoption of financials, board elections, LTIP programs, share authorizations, etc.). It is not the full AGM slide deck or financial report itself but an official announcement of the voting outcomes and resolutions from the AGM. Hence it fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-12 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 100% confidence The document is a notification from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a shareholder's holdings in XSpray Pharma AB. It details the number of shares and voting rights held before and after a transaction, the percentage ownership, and the legal basis for the disclosure. The document is a flagging notification about share ownership crossing a threshold, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding information, with no financial statements or other report content. Therefore, it is classified as MRQ with high confidence.
2026-05-04 Swedish
Nytt antal aktier och röster i Xspray Pharma efter nyemission april 2026
Share Issue/Capital Change Classification · 100% confidence The document is a press release dated April 30, 2026, announcing a change in the number of shares and voting rights in Xspray Pharma following a new share issuance (nyemission). It details the increase in outstanding shares and share capital due to a rights issue and overallotment. The content focuses on capital structure changes and share issuance, with no financial statements or detailed financial performance data. The document length is short (2413 characters) and it is clearly an announcement of a capital change event rather than a full financial report or detailed investor presentation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2026-04-30 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.